Barclays raised price target on Hims & Hers Health and announced a partnership to sell weight-loss drugs via its platform.
1 report, 1 independent
Updated Jun 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Barclays raised price target on Hims & Hers Health and announced a partnership to sell weight-loss drugs via its platform.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Hims & Hers Health
American telehealth company
Nothing else this week.
-
Barclays
British bank
- QinetiQ carried out share purchases and arranged for a share buyback execution on the London Stock Exchange.
- Financial institutions provided ratings on multiple companies on July 8, 2026, including Goldman Sachs reiterating Tesla as neutral, Barclays initiating Toast as overweight, and Bank of America rating Nvidia as a buy.
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Barclays raised its price target on Latham Group on September 1, 2026.
- Barclays maintained Overweight rating and raised price target on August 29, 2025.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Barclays set a price target for Hawkins shares, and VP Douglas Lange bought shares of the company.